Thrombospondin-2 (THBS2) is a multifunctional extracellular matrix glycoprotein encoded by the *THBS2* gene. It belongs to the thrombospondin family, known for regulating cell-matrix interactions, angiogenesis, and tissue remodeling. Unlike its paralog THBS1 (TSP-1), THBS2 lacks the anti-angiogenic N-terminal domain but shares conserved domains involved in binding integrins, collagen, and growth factors. THBS2 is secreted by stromal cells, fibroblasts, and immune cells, influencing processes like wound healing, inflammation, and tumor progression. It modulates extracellular matrix organization by interacting with matrix metalloproteinases (MMPs) and inhibiting excessive angiogenesis, contributing to tissue homeostasis.
THBS2 is implicated in various pathologies. Overexpression is linked to fibrosis in organs like the liver and lungs, while its role in cancer is context-dependent: it can suppress tumor growth by normalizing vasculature or promote metastasis by enhancing invasive microenvironments. Studies highlight THBS2 as a potential biomarker for cancers (e.g., pancreatic, ovarian) and fibrotic diseases.
THBS2 antibodies are vital tools for detecting this protein in research and diagnostics. They are used in techniques like Western blotting, immunohistochemistry, and ELISA to study THBS2 expression patterns, interactions, and roles in disease mechanisms. Both polyclonal and monoclonal antibodies are available, often generated in rabbits or mice. These reagents aid in elucidating THBS2's complex functions, offering insights into therapeutic targeting of fibrosis, cancer, and vascular disorders.